<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524329</url>
  </required_header>
  <id_info>
    <org_study_id>N13</org_study_id>
    <nct_id>NCT00524329</nct_id>
  </id_info>
  <brief_title>Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage</brief_title>
  <acronym>Synchronise</acronym>
  <official_title>SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the treatment effect in patients with upper
      gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those
      without an elevated risk for NSAID-associated damage (as determined by the treating
      physician).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">1220</enrollment>
  <condition>Heartburn</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting at general practitioner
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with upper gastro-intestinal complaints (defined as heartburn and/or
             regurgitation and/or nausea and/or bloated feeling)and treatment with esomeprazole
             20mg once daily is started because of this (consult 1). Upper gastro-intestinal
             complaints are thought to be related to NSAID use

          -  Patient is using an NSAID** with the following conditions:

               -  NSAID use has started at least one week before 1st consultation and is expected
                  to be continued unchanged during the coming period (at least until consult 2)

               -  NSAID is taken at least 3 days a week

        (**)OTC or Prescription NSAID

        (**)Conventional NSAID or COX-2 selective NSAID

        Exclusion Criteria:

          -  Use of a PPI and/or H2RA in the month preceding the study

          -  A history of reflux disease, not related to NSAID use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Sellink</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N van den Berk</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tore Lind / Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>upper GI-symptoms</keyword>
  <keyword>heartburn</keyword>
  <keyword>NSAID</keyword>
  <keyword>risk</keyword>
  <keyword>PPI</keyword>
  <keyword>Bloating</keyword>
  <keyword>Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

